Skip to content
DataLookout
Menu

T4MSNCT04798651

Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 4 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Sep 2026 to Sep 2027
    • Eligibility criteria expanded, about 8 words
  2. Minor Site contact updatedv4
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Mar 2021 to Sep 30, 2021
    • Primary and study completion dates: Mar 2026 to Sep 2026
    • Site details revised
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Functional and phenotypical characterization of the blood and CSF lymphocytes in MS and CIS patients.
Timeframe: At inclusion (day 0)

Secondary (10)

Quantification of disease activity scores
Number of lesions
Size of lesions
Localisation of lesions
Types of lesions
Show 5 moreShow less
duration of the disease
age at onset and progression
number of relapses
date of relapses
Treatment

Arms and interventions

patients with multiple sclerosis or clinically isolated syndromeExperimental

subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome

Biologicals: blood sample, cerebro-spinal fluid

Sites

1 site in 1 country

  • CHU de Bordeaux - service de neurologieBordeaux, France